Association between biomarkers of zinc and copper status and heart failure: a meta‐analysis

Abstract

AbstractAimsPrevious studies have investigated the relationship between heart failure (HF) and levels of zinc and copper, but conflicting results have been reported. This meta‐analysis aims to clarify the role of zinc and copper in HF progression by examining the associations between HF and concentrations of these minerals.Methods and resultsWe utilized STATA 12.0 software to calculate the standard mean difference (SMD) and 95% confidence interval (CI) for serum zinc and copper levels in patients with HF compared with healthy controls (HCs). The meta‐analysis indicated a lower serum zinc level in patients with HF compared with HCs, using a random effects model (SMD = −0.77; 95% CI: −1.01, −0.54; I2 = 61.9%, the P‐value for Q test = 0.002). Additionally, the meta‐analysis showed an increased serum copper level in patients with HF compared with HCs, using a random effects model (SMD = 0.66; 95% CI: 0.09, 1.23; I2 = 93.8%, the P‐value for Q test < 0.001). Meta‐regression analysis indicated that publication year, age, and gender were not responsible for heterogeneity across studies.ConclusionsThis meta‐analysis demonstrates that patients with HF have lower serum zinc and higher copper concentrations compared with healthy subjects. However, the potential of zinc supplementation as a therapy for HF should be approached with caution. The heterogeneity among the included studies was found to be high. It is recommended that further well‐designed large sample studies be conducted to validate these findings.